de Jonge Nick A, Janssen Jeroen J W M, Ypma Paula, Herbers Alexandra H E, de Kreuk Arne, Vasmel Wies, van den Ouweland Jody M W, Beeker Aart, Visser Otto, Zweegman Sonja, Blijlevens Nicole M A, van Agtmael Michiel A, Sikkens Jonne J
Department of Haematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, the Netherlands.
Support Care Cancer. 2024 Aug 8;32(9):579. doi: 10.1007/s00520-024-08776-w.
Haematology patients with high-risk neutropenia are prone to mucosal-barrier injury-associated laboratory-confirmed bloodstream infections (MBI-LCBI). We assessed risk factors for MBI-LCBI including candidaemia in neutropenic haematology patients with fever.
This prospective observational study was performed in six dedicated haematology units in the Netherlands. Eligible haematology patients had neutropenia < 500/mL for ≥ 7 days and had fever. MBI-LCBIs were classified according to Centers for Disease Control (CDC) definitions and were followed until the end of neutropenia > 500/mL or discharge.
We included 416 patients from December 2014 until August 2019. We observed 63 MBI-LCBIs. Neither clinical mucositis scores nor the blood level of citrulline at fever onset was associated with MBI-LCBI. In the multivariable analysis, MASCC-score (odds ratio [OR] 1.16, 95% confidence interval [CI] 1.05 to 1.29 per point decrease), intensive chemotherapy (OR 3·81, 95% CI 2.10 to 6.90) and Pichia kudriavzevii (formerly Candida krusei) colonisation (OR 5.40, 95% CI 1.75 to 16.7) were retained as risk factors for MBI-LCBI, while quinolone use seemed protective (OR 0.42, 95% CI 0.20 to 0.92). Citrulline level (OR 1.57, 95% CI 1.07 to 2.31 per µmol/L decrease), active chronic obstructive pulmonary disease (OR 15.4, 95% CI 1.61 to 14.7) and colonisation with fluconazole-resistant Candida (OR 8.54, 95% CI 1.51 to 48.4) were associated with candidaemia.
In haematology patients with fever during neutropenia, hypocitrullinaemia at fever onset was associated with candidaemia, but not with bacterial MBI-LCBI. Patients with intensive chemotherapy with a low MASCC-score and colonisation with Pichia kudriavzevii had the highest risk of MBI-LCBI.
ClinicalTrials.gov (NCT02149329) at 19-NOV-2014.
高危中性粒细胞减少的血液学患者易发生与黏膜屏障损伤相关的实验室确诊血流感染(MBI-LCBI)。我们评估了MBI-LCBI的危险因素,包括中性粒细胞减少且发热的血液学患者的念珠菌血症。
这项前瞻性观察性研究在荷兰的六个专门血液学科室进行。符合条件的血液学患者中性粒细胞减少<500/mL持续≥7天且发热。MBI-LCBI根据疾病控制中心(CDC)的定义进行分类,并随访至中性粒细胞>500/mL结束或出院。
我们纳入了2014年12月至2019年8月的416例患者。我们观察到63例MBI-LCBI。发热开始时的临床黏膜炎评分和瓜氨酸血水平均与MBI-LCBI无关。在多变量分析中,MASCC评分(每降低一分优势比[OR]1.16,95%置信区间[CI]1.05至1.29)、强化化疗(OR 3.81,95%CI 2.10至6.90)和库德里亚夫齐毕赤酵母(原克鲁斯念珠菌)定植(OR 5.40,95%CI 1.75至16.7)被保留为MBI-LCBI的危险因素,而使用喹诺酮似乎具有保护作用(OR 0.42,95%CI 0.20至0.92)。瓜氨酸水平(每降低1µmol/L OR 1.57,95%CI 1.07至2.31)、活动性慢性阻塞性肺疾病(OR 15.4,95%CI 1.61至14.7)和耐氟康唑念珠菌定植(OR 8.54,95%CI 1.51至48.4)与念珠菌血症相关。
在中性粒细胞减少期间发热的血液学患者中,发热开始时的低瓜氨酸血症与念珠菌血症相关,但与细菌性MBI-LCBI无关。强化化疗、MASCC评分低且有库德里亚夫齐毕赤酵母定植的患者发生MBI-LCBI的风险最高。
ClinicalTrials.gov(NCT02149329)于2014年11月19日注册。